Treating COVID with Metformin Reduces Long COVID Rates
MINNEAPOLIS, June 9, 2023 /PRNewswire/ -- A new study published in The Lancet Infectious Diseases supported by the Parsemus Foundation found a 41% reduction in Long COVID rates among people who used metformin at the time of COVID infection.
- MINNEAPOLIS, June 9, 2023 /PRNewswire/ -- A new study published in The Lancet Infectious Diseases supported by the Parsemus Foundation found a 41% reduction in Long COVID rates among people who used metformin at the time of COVID infection.
- The randomized, quadruple-blinded, placebo-controlled clinical trial was the first in the country to study whether these medications could prevent severe outcomes and Long COVID.
- The trial found that people who took metformin within seven days after the onset of COVID symptoms were 41% less likely to experience Long COVID than those who had placebo—with a 63% reduction if metformin was started within four days.
- As the first COVID treatment proven to reduce Long COVID in a randomized controlled trial, metformin is safe, accessible and low-cost.